Acadian Asset Management LLC Acquires 80,478 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Acadian Asset Management LLC lifted its position in United Therapeutics Co. (NASDAQ:UTHR) by 255.7% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 111,956 shares of the biotechnology company’s stock after purchasing an additional 80,478 shares during the period. Acadian Asset Management LLC owned about 0.25% of United Therapeutics worth $25,707,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Rise Advisors LLC purchased a new position in shares of United Therapeutics in the 1st quarter worth about $32,000. GAMMA Investing LLC bought a new stake in United Therapeutics in the 4th quarter worth about $43,000. Benjamin F. Edwards & Company Inc. increased its holdings in United Therapeutics by 63.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after buying an additional 117 shares in the last quarter. Janiczek Wealth Management LLC increased its holdings in United Therapeutics by 21.1% in the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after buying an additional 84 shares in the last quarter. Finally, Blue Trust Inc. increased its holdings in United Therapeutics by 10.0% in the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock worth $114,000 after buying an additional 46 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

UTHR stock traded up $2.84 during trading on Monday, hitting $332.00. 152,037 shares of the company traded hands, compared to its average volume of 493,678. The stock’s 50-day simple moving average is $296.57 and its 200 day simple moving average is $253.93. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The company has a market cap of $14.73 billion, a PE ratio of 15.63, a P/E/G ratio of 1.44 and a beta of 0.55. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $339.56.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. During the same period in the previous year, the business earned $4.86 earnings per share. The business’s revenue was up 33.7% compared to the same quarter last year. On average, equities analysts expect that United Therapeutics Co. will post 24.87 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other United Therapeutics news, Director Christopher Causey sold 2,240 shares of the business’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $259.91, for a total transaction of $582,198.40. Following the transaction, the director now owns 4,185 shares of the company’s stock, valued at $1,087,723.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Christopher Causey sold 2,240 shares of the company’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $259.91, for a total value of $582,198.40. Following the transaction, the director now owns 4,185 shares of the company’s stock, valued at approximately $1,087,723.35. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Christopher Patusky sold 1,310 shares of the business’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $264.35, for a total value of $346,298.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 100,884 shares of company stock valued at $28,934,087. Insiders own 12.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Oppenheimer boosted their price target on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. TD Cowen boosted their price target on United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. UBS Group boosted their price target on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research note on Monday, July 8th. Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $310.00 to $321.00 in a research report on Thursday, July 11th. Finally, The Goldman Sachs Group lifted their price objective on United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Two research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $321.55.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.